ReviewCritical reviews in oncogenesis2015
Biology and Treatment of Rhabdoid Tumor.
Review in Critical reviews in oncogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- A review of Leila Rose Foundation support for families affected by rare childhood cancer in Australia over the past decade.Cancer reports (Hoboken, N.J.) · 2022Pooled it
- Atypical teratoid/rhabdoid tumor in adults: a systematic review of the literature with meta-analysis and additional reports of 4 cases.Journal of neuro-oncology · 2022Pooled it
- Prognostic value of dysadherin in cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer.Journal of clinical medicine · 2026Review
- Clinical Impact of Germline Multigene Sequencing in Pediatric Cohorts with a Wide Spectrum of Neoplasms.International journal of molecular sciences · 2026Article
- Rhabdoid tumors as a novel target for PSMA-directed CAR T cell therapy.Molecular therapy. Oncology · 2026Article
- Targeting CDK11 in Rhabdoid Tumor of the Kidney.Cancers · 2026Article
- Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney.Frontiers in pediatrics · 2026Review
- Rhabdoid Tumor Predisposition Syndrome : A Comprehensive Review of Genetics, Clinical Manifestations, and Management.Journal of Korean Neurosurgical Society · 2025Article
- A Recent Overview of Molecular Pathways in Synthetic Lethality as a Proposed Valid Target in Oncology: Current Insights and Future Directions.Indian journal of surgical oncology · 2025Review
- SMARCB1/INI1-deficient lung cancer with lymph node metastasis: a case report and literature review.AME case reports · 2025Article
- SMARCB1-Retained and SMARCB1-Deficient SNUC are Genetically Distinct: A Pilot Study Using RNA Sequencing.Journal of neurological surgery. Part B, Skull base · 2024Article
- Rhabdoid tumor predisposition syndrome: A historical review of treatments and outcomes for associated pediatric malignancies.Pediatric blood & cancer · 2024Review
- Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors.Cancers · 2024Article
- Enhancing drug and cell line representations via contrastive learning for improved anti-cancer drug prioritization.NPJ precision oncology · 2024Article
- Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors.Scientific reports · 2023Article
- Primary Malignant Rhabdoid Tumor of the Liver in a 5-Month-Old Female Who Presented with Abdominal Distension.The American journal of case reports · 2023Article
- The role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours.Journal of cancer research and clinical oncology · 2023Article
- Extrarenal malignant rhabdoid tumor infiltrating the brachial plexus and spinal canal.The neuroradiology journal · 2023Article
- CT and MR imaging features of soft tissue rhabdoid tumor: compared with rhabdomyosarcoma in children.Frontiers in pediatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Rhabdoid tumor is a rare, highly aggressive malignancy that primarily affects infants and young children. These tumors typically arise in the brain and kidney, although extrarenal, non-central nervous system tumors in almost all soft-tissue sites have been described. SMARCB1 is a member of the SWI/SNF chromatin-remodeling complex and functions as a tumor suppressor in the vast majority of rhabdoid tumors. Patients with germline mutations or deletions affecting SMARCB1 are predisposed to the development of rhabdoid tumors, as well as the genetic disorder schwannomatosis. The current hypothesis is that rhabdoid tumors are driven by epigenetic dysregulation, as opposed to the alteration of a specific biologic pathway. The strategies for novel therapeutic approaches based on what is currently known about rhabdoid tumor biology are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.